The primary aim of this study will be to examine the diagnostic utility of 18-F Florbetapir PET/MR (Positron Emission Tomography/Magnetic Resonance) in imaging patients with pathologically-confirmed systemic amyloidosis involving the peripheral nerves and compare these results to non-amyloid diseased controls.
Patients with pathologically proven amyloidosis involving the peripheral nervous system will undergo 18-F Florbetapir PET/MR on a GE (General Electric Healthcare) SIGNA PET/MR scanner. A control arm comprised of patients with pathologically-confirmed non-amyloid causes of peripheral neuropathy will also undergo 18-F Florbetapir PET/MR scanning. all images will be reviewed for peripheral nerve uptake.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
8
18-F Florbetapir PET/MR scan, PET/MR on a GE SIGNA PET/MR scanner
Mayo Clinic in Rochester
Rochester, Minnesota, United States
Locations of peripheral nerve 18-F Florbetapir uptake
Standardized uptake value (SUV)
Time frame: 50-120 minutes post injection
Pattern of F-18 Florbetapir uptake (Heterogeneous vs. Homogeneous, focal vs. diffuse)
Heterogeneous vs. Homogeneous, focal vs. diffuse. This is a categorical variable. There is not a quantitative or semi-quantitative scale that is appropriate.
Time frame: 50-120 minutes post injection
T1 and T2 characteristics (Hypointense, isointense or hyperintense relative to skeletal muscle)
Hypointense, isointense or hyperintense relative to skeletal muscle. This is a categorical variable. There is not a quantitative or semi-quantitative scale that is appropriate.
Time frame: 50-120 minutes post injection
Morphologic changes
Presence or absence of neural enlargement
Time frame: 50-120 minutes post injection
Pattern of contrast enhancement (Solid, heterogeneous or peripheral enhancement)
Solid, heterogeneous or peripheral enhancement. This is a categorical variable. There is not a quantitative or semi-quantitative scale that is appropriate.
Time frame: 50-120 minutes post injection
Additional sites of 18-F Florbetapir uptake
i.e. cardiac myocardium, skeletal muscle, bone marrow
Time frame: 50-120 minutes post injection
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.